AIMS/HYPOTHESIS: The recent discovery of two adiponectin receptors (AdipoR1 and AdipoR2) will improve our understanding of the molecular mechanisms underlying the insulin-sensitising effect of adiponectin. The aim of this study was to determine for the first time whether skeletal muscle AdipoR1 and/or AdipoR2 gene expression levels are associated with insulin resistance. METHODS: Using RT-PCR and northern analysis we measured AdipoR1 and AdipoR2 gene expression in skeletal muscle from healthy Mexican Americans with normal glucose tolerance who had (n=8) or did not have (n=10) a family history of Type 2 diabetes. RESULTS: Gene expression profiling indicated that the AdipoR1 and AdipoR2 isoforms are highly expressed in human skeletal muscle, unlike in mice where AdipoR2 expression was highest in the liver, and AdipoR1 was highest in skeletal muscle. In the study subjects, the expression levels of AdipoR1 (p=0.004) and AdipoR2 (p=0.04), as well as plasma adiponectin concentration (p=0.03) were lower in people with a family history of Type 2 diabetes than in those with no family history of the disease. Importantly, the expression levels of both receptors correlated positively with insulin sensitivity (r=0.64, p=0.004 and r=0.47, p=0.048 respectively). CONCLUSIONS/ INTERPRETATION: Collectively, these data indicate that both isoforms of the adiponectin receptor play a role in the insulin-sensitising effect of adiponectin.
AIMS/HYPOTHESIS: The recent discovery of two adiponectin receptors (AdipoR1 and AdipoR2) will improve our understanding of the molecular mechanisms underlying the insulin-sensitising effect of adiponectin. The aim of this study was to determine for the first time whether skeletal muscle AdipoR1 and/or AdipoR2 gene expression levels are associated with insulin resistance. METHODS: Using RT-PCR and northern analysis we measured AdipoR1 and AdipoR2 gene expression in skeletal muscle from healthy Mexican Americans with normal glucose tolerance who had (n=8) or did not have (n=10) a family history of Type 2 diabetes. RESULTS: Gene expression profiling indicated that the AdipoR1 and AdipoR2 isoforms are highly expressed in human skeletal muscle, unlike in mice where AdipoR2 expression was highest in the liver, and AdipoR1 was highest in skeletal muscle. In the study subjects, the expression levels of AdipoR1 (p=0.004) and AdipoR2 (p=0.04), as well as plasma adiponectin concentration (p=0.03) were lower in people with a family history of Type 2 diabetes than in those with no family history of the disease. Importantly, the expression levels of both receptors correlated positively with insulin sensitivity (r=0.64, p=0.004 and r=0.47, p=0.048 respectively). CONCLUSIONS/ INTERPRETATION: Collectively, these data indicate that both isoforms of the adiponectin receptor play a role in the insulin-sensitising effect of adiponectin.
Authors: K Maeda; K Okubo; I Shimomura; T Funahashi; Y Matsuzawa; K Matsubara Journal: Biochem Biophys Res Commun Date: 1996-04-16 Impact factor: 3.575
Authors: W Pratipanawatr; T Pratipanawatr; K Cusi; R Berria; J M Adams; C P Jenkinson; K Maezono; R A DeFronzo; L J Mandarino Journal: Diabetes Date: 2001-11 Impact factor: 9.461
Authors: C Weyer; T Funahashi; S Tanaka; K Hotta; Y Matsuzawa; R E Pratley; P A Tataranni Journal: J Clin Endocrinol Metab Date: 2001-05 Impact factor: 5.958
Authors: Robert S Lindsay; Tohru Funahashi; Robert L Hanson; Yuji Matsuzawa; Sachiyo Tanaka; P Antonio Tataranni; William C Knowler; Jonathan Krakoff Journal: Lancet Date: 2002-07-06 Impact factor: 79.321
Authors: J Fruebis; T S Tsao; S Javorschi; D Ebbets-Reed; M R Erickson; F T Yen; B E Bihain; H F Lodish Journal: Proc Natl Acad Sci U S A Date: 2001-02-06 Impact factor: 11.205
Authors: T Yamauchi; J Kamon; H Waki; Y Terauchi; N Kubota; K Hara; Y Mori; T Ide; K Murakami; N Tsuboyama-Kasaoka; O Ezaki; Y Akanuma; O Gavrilova; C Vinson; M L Reitman; H Kagechika; K Shudo; M Yoda; Y Nakano; K Tobe; R Nagai; S Kimura; M Tomita; P Froguel; T Kadowaki Journal: Nat Med Date: 2001-08 Impact factor: 53.440
Authors: T Yamauchi; J Kamon; Y Minokoshi; Y Ito; H Waki; S Uchida; S Yamashita; M Noda; S Kita; K Ueki; K Eto; Y Akanuma; P Froguel; F Foufelle; P Ferre; D Carling; S Kimura; R Nagai; B B Kahn; T Kadowaki Journal: Nat Med Date: 2002-10-07 Impact factor: 53.440
Authors: S Matsui; T Yasui; A Tani; T Kato; K Kunimi; H Uemura; A Kuwahara; T Matsuzaki; M Irahara Journal: J Endocrinol Invest Date: 2013-06-10 Impact factor: 4.256
Authors: Anthony E Civitarese; Barbara Ukropcova; Stacy Carling; Matthew Hulver; Ralph A DeFronzo; Lawrence Mandarino; Eric Ravussin; Steve R Smith Journal: Cell Metab Date: 2006-07 Impact factor: 27.287
Authors: N Stefan; F Machicao; H Staiger; J Machann; F Schick; O Tschritter; C Spieth; C Weigert; A Fritsche; M Stumvoll; H U Häring Journal: Diabetologia Date: 2005-10-05 Impact factor: 10.122
Authors: C Koebnick; L A Kelly; C J Lane; C K Roberts; G Q Shaibi; C M Toledo-Corral; J N Davis; M J Weigensberg; M I Goran Journal: Diabet Med Date: 2008-09 Impact factor: 4.359